In the evolving field of metabolic medicine, the focus is expanding beyond traditional GLP-1 agonists to novel mechanisms of action. One of the most discussed compounds in 2026 is 5-Amino-1MQ (5-amino-1-methylquinolinium iodide). Often grouped with peptides in clinical discussions, 5-Amino-1MQ is actually a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT) [1]. This article examines […]
